Enovis vs Inogen
ENOV and INGN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and INGN compare
Enovis is the larger company, worth 10 times as much as Inogen ($1.6B against $151M).
Enovis grew revenue faster over the last twelve months (4.9% versus 3.2% for Inogen).
Inogen keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −48.0% at Enovis.
Inogen scores higher on the StockData Score (11 against 8 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | INGN |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $151M |
| Share price | $27.22 | $5.68 |
| Change, 1 year | −9.2% | −17.6% |
| Change, 5 years | −81.3% | −82.2% |
| Beta (5Y) | 0.08 | 0.34 |
| Employees | 7,802 | 314 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | 0.4× (better) |
| P/B | 1.1× | 0.9× (better) |
| EV/EBITDA | 9.2× | – |
| P/FCF | 24.7× | – |
| FCF yield | 4.1% (better) | −3.3% |
| Fair value | $81.07 | $17.84 |
| Margin of safety | 66.4% | 68.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.9% (better) | 3.2% |
| Revenue growth, 5Y average | 14.9% (better) | 2.5% |
| Profitability | ||
| Gross margin | 61.1% (better) | 44.5% |
| Operating margin | −45.1% | −8.7% (better) |
| Net margin | −48.0% | −6.9% (better) |
| FCF margin | 2.8% (better) | −1.4% |
| Return on equity | −54.3% | −13.1% (better) |
| Return on invested capital | −24.5% (better) | −33.3% |
| Financial health | ||
| Debt / equity | 0.87 (better) | 0.00 |
| Net debt / EBITDA | 4.12 | – |
| Interest coverage | −30.9× | – |
| Current ratio | 1.98 | 2.74 (better) |
| Altman Z-score | −0.24 | 1.30 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 122% | 72.9% |
| Held by insiders | 2.7% | 3.7% |
| Insider net buying, 12 months | $842K (better) | −$143K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 18.8% | 5.5% |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- INGN stock overview
- INGN income statement
- INGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.